Microsoft is discontinuing the Contact Masking feature in Outlook. Previously hidden recipients will reappear in suggestions ...

Fourth quarter of 2025 revenue increased 70.2% year-over-year to $12.0 million, with record quarterly gross margin of 58.5% Net income from ...

Overall, we have raised a total of $472.2 million in net proceeds from the sale of 12 container vessels since December 2023, and have recycled this capital into our focus on gas transportation assets.

Thank you, John, and thanks to everyone for joining our call. After a thorough search for a permanent CEO by a leading ...

After an initial flurry of moves, the NFL free agent market has slowed down. Here are the teams that have made the biggest ...

SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage biopharmaceutical company developing a fully human anti-thymocyte ...

A busy first week of the NFL offseason is in the books. Dan Wilkins, theScore's senior NFL writer, puts all the action into ...

Q4 2025 earnings call recap: net sales +9%, 2026 guidance up to $80M EBITDA, margin outlook, tariffs, growth plans—read now.

Shares higher as five members vote to raise rates and four members vote against; ANZ consumer confidence the lowest since 2020; watch RBA governor speak after rate rise. Follow live.

Science Applications International Corporation (NASDAQ:SAIC) Q4 2026 Earnings Call Transcript March 16, 2026 Science Applications International Corporation beats earnings expectations. Reported EPS is ...

Q4 2025 Earnings Call March 12, 2026 5:00 PM EDTCompany ParticipantsBradley Korch - Senior VP of Finance & Head of ...

SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage biopharmaceutical company developing a fully human anti-thymocyte immunoglobulin (hATG) for type 1 diabetes (T1D) and other autoimmune ...